Elias Jabbour, MD- Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX
Elias Jabbour, MD discussed the potential treatment options for patients facing relapsed leukemia during a medical presentation. He emphasized the importance of considering complementary strategies rather than competing ones. Dr. Jabbour advocated starting with bispecific and immunotherapy approaches before utilizing CAR T-cell therapy due to their positive impact on survival. He referred to the dire prognosis of relapsed patients, comparing it to a death sentence, and highlighted the challenges associated with traditional treatments like transplantation.
Dr. Jabbour outlined a series of treatment modifications and regimens aimed at improving patient outcomes. He detailed the use of aneurysmab and chemotherapy cycles, demonstrating a shift in dosing and administration patterns. He also presented data from studies on the effectiveness of these approaches, focusing on response rates, minimal residual disease (MRD) negativity, and overall survival.